"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 7 | 7 |
| 1996 | 6 | 10 | 16 |
| 1997 | 4 | 9 | 13 |
| 1998 | 2 | 7 | 9 |
| 1999 | 1 | 6 | 7 |
| 2000 | 2 | 12 | 14 |
| 2001 | 4 | 7 | 11 |
| 2002 | 2 | 10 | 12 |
| 2003 | 1 | 7 | 8 |
| 2004 | 9 | 11 | 20 |
| 2005 | 6 | 17 | 23 |
| 2006 | 2 | 18 | 20 |
| 2007 | 6 | 13 | 19 |
| 2008 | 7 | 28 | 35 |
| 2009 | 9 | 29 | 38 |
| 2010 | 9 | 23 | 32 |
| 2011 | 8 | 26 | 34 |
| 2012 | 5 | 27 | 32 |
| 2013 | 4 | 21 | 25 |
| 2014 | 5 | 16 | 21 |
| 2015 | 16 | 22 | 38 |
| 2016 | 14 | 25 | 39 |
| 2017 | 4 | 21 | 25 |
| 2018 | 16 | 23 | 39 |
| 2019 | 6 | 29 | 35 |
| 2020 | 8 | 15 | 23 |
| 2021 | 12 | 23 | 35 |
| 2022 | 0 | 30 | 30 |
| 2023 | 0 | 15 | 15 |
| 2024 | 8 | 16 | 24 |
| 2025 | 1 | 1 | 2 |
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025 Jan 15; 131(2):e35713.
-
Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study-5 and Children's Oncology Group Study AREN0321. Pediatr Blood Cancer. 2025 Mar; 72(3):e31490.
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
-
Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical Trial. Pediatr Blood Cancer. 2025 Feb; 72(2):e31436.
-
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS. Lupus Sci Med. 2024 Nov 09; 11(2).
-
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis. Transplant Cell Ther. 2024 Nov; 30(11):1092-1098.
-
Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus. Transplant Proc. 2024 Sep; 56(7):1671-1677.